Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajesh Kabra

Clinical Cardiac Electrophysiology Memphis, TN Medical Doctor

NPI 1144231820 CMS profile 278954

1407 Union Ave, Suite 200, Memphis, TN 38104

Open in the dashboard

General payments

$42,402

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$59,632 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Rajesh Kabra of Memphis, TN is reported in the CMS Open Payments database as having received $42,402 across 334 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $59,632 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,107 55
2024 General $4,502 72
2023 General $6,129 95
2022 General $4,561 51
2021 General $343 14
2020 General $3,707 15
2019 General $14,052 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajesh Kabra
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Rajesh Kabra were reported at $9,107. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Rajesh Kabra Clinical Cardiac Electrophysiology median Middle half National median
2019 $14,052 $2,361 $585–$8,260 $163
2020 $3,707 $993 $247–$4,351 $114
2021 $343 $1,185 $326–$4,739 $132
2022 $4,561 $2,073 $554–$6,789 $149
2023 $6,129 $2,568 $759–$8,159 $160
2024 $4,502 $2,557 $703–$7,403 $164
2025 $9,107 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $27,847 129 payments
  2. Medical Device Business Services, Inc. $3,225 8 payments
  3. Volta Medical Inc $3,090 11 payments
  4. Medtronic, Inc. $2,268 46 payments
  5. AltaThera Pharmaceuticals LLC $1,733 2 payments
  6. Biosense Webster, Inc. $1,261 26 payments
  7. Boston Scientific Corporation $787 37 payments
  8. Acutus Medical, Inc. $395 2 payments
  9. Atricure, Inc. $316 3 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $265 17 payments
  11. Other $1,215 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,749 14 payments
  2. Food and Beverage $10,651 271 payments
  3. Travel and Lodging $6,964 38 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,888 2 payments
  5. Honoraria $2,674 8 payments
  6. Education $477 1 payment
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $10,958 13 payments
  2. TACTICATH ABLATION CATHETER, SENSOR ENABLED $5,729 7 payments
  3. TactiCath Quartz CFA Catheter $4,050 3 payments
  4. VX1 $2,967 10 payments
  5. AVEIR Cardiac Rhythm Management $2,819 22 payments
  6. Carto 3 $2,467 23 payments
  7. Carto 3 System $1,896 11 payments
  8. Sotalol Hydrochloride $1,733 2 payments
  9. AMPLATZER AMULET $808 16 payments
  10. AVEIR Cardiac Rhythm Management $577 6 payments
  11. Other $7,412 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,184

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$300,436

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

39.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 239 $250,448
Xarelto Rivaroxaban Brand 26 $34,768
Dofetilide Generic 49 $6,029
Metoprolol Succinate Generic 331 $3,397
Sotalol Sotalol Hcl Brand 64 $926
Flecainide Acetate Generic 29 $808
Diltiazem 24hr Er (La) Diltiazem Hcl Brand 11 $664
Amiodarone Hcl Generic 28 $613
Clopidogrel Clopidogrel Bisulfate Brand 80 $550
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 18 $383

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$249,608

Medicare's payments for the services billed

Medicare patients

676

Average age 76

Services billed

2,508

338 women, 338 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 53%
Arthritis 51%
Heart failure 45%
Chronic kidney disease 39%
Diabetes 36%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $46
$46 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$17 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $17
$17 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $15
$15 239 —
XARELTO
  • Janssen Pharmaceuticals, Inc $14
$14 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record